MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Catalyst Pharmaceuticals Inc

Închisă

SectorSănătate

20.95 -2.24

Rezumat

Modificarea prețului

24h

Curent

Minim

20.8

Maxim

21.43

Indicatori cheie

By Trading Economics

Venit

801K

57M

Vânzări

-399K

141M

P/E

Medie Sector

13.822

40.527

Marjă de profit

40.119

Angajați

181

EBITDA

526K

73M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+55.31% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-383M

2.6B

Deschiderea anterioară

23.19

Închiderea anterioară

20.95

Sentimentul știrilor

By Acuity

50%

50%

143 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 iul. 2025, 15:29 UTC

Principalele dinamici ale pieței

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 iul. 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 iul. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 iul. 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 iul. 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7 iul. 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 iul. 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7 iul. 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 iul. 2025, 21:34 UTC

Achiziții, Fuziuni, Preluări

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 iul. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 iul. 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 iul. 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 iul. 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 iul. 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7 iul. 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 iul. 2025, 16:53 UTC

Câștiguri

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 iul. 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 iul. 2025, 16:05 UTC

Achiziții, Fuziuni, Preluări

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 iul. 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 iul. 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 iul. 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 iul. 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 iul. 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 iul. 2025, 15:14 UTC

Achiziții, Fuziuni, Preluări

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 iul. 2025, 15:00 UTC

Achiziții, Fuziuni, Preluări

GSK Completes Acquisition of Efimosfermin

7 iul. 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 iul. 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 iul. 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Comparație

Modificare preț

Catalyst Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

55.31% sus

Prognoză pe 12 luni

Medie 33.33 USD  55.31%

Maxim 35 USD

Minim 31 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCatalyst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 24.28Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

143 / 375 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.